SLC5A2 and type 2 diabetes mellitus: In conclusion, given the potential seriousness of dapagliflozin-induced ketoacidosis and considering the intrinsic limitations of our study, we believe that further high-quality clinical studies should be conducted on this topic, especially in T2DM patients, to better estimate the impact of SGLT2 inhibitors on diabetic ketoacidosis.